Amgen's Otezla bags expanded FDA nod in psoriasis; I-Mab CEO hits the exit amid shakeup at Chinese firm
Just a few weeks after Otezla notched a Phase III win and hit all primary and secondary endpoints for a trial in genital psoriasis, Amgen’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
